BUKWANG PHARMACEUTICAL CO
Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a healthy financial status and stable track record that earned trust from its employees and shareholders. Bukwang’s operating profit is at the top of the rank in the industry, nearing 20% as of financial year 2014. ... Bukwang’s armamentarium consists of more than 100 products in various therapeutic areas: liver disease treatments such as Levovir and Legalon, diabetic complication products such as Dexid and Thioctacid, CNS disorder drugs including Lonasen, Ixel and Orfil, and respiratory disease treatments such as Azeptin and Asima. Bukwang continues to grow its original drug business through consistent focus on new drug development.
BUKWANG PHARMACEUTICAL CO
Industry:
Manufacturing Medical Device
Founded:
1960-01-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.bukwang.co.kr
Total Employee:
501+
Status:
Active
Contact:
(028)288-029
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro GStatic Google Static Content COVID-19 IIS Pound Sterling
Similar Organizations
Inogen
Inogen is a manufacturer and an accredited homecare provider dedicated to oxygen therapy.
Jaber Ibn Hayyan Pharmaceutical
Jaber Ibn Hayyan Pharmaceutical manufactures drugs like anti-biotic, non-antibiotic , topical, oral and others.
Nipro Corporation
Nipro Corporation manufactures medical devices, pharmaceuticals and instrument products.
Current Employees Featured
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-11-28 | Contera Pharma | Contera Pharma acquired by Bukwang Pharmaceutical Co | N/A |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-01-20 | ImmPACT Bio | Bukwang Pharmaceutical Co investment in Series B - ImmPACT Bio | 111 M USD |
| 2020-08-18 | ImmPACT Bio | Bukwang Pharmaceutical Co investment in Series A - ImmPACT Bio | 18 M USD |
| 2019-11-12 | Protekt Therapeutics | Bukwang Pharmaceutical Co investment in Venture Round - Protekt Therapeutics | 4.1 M USD |
Official Site Inspections
http://www.bukwang.co.kr
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
